Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill reauthorizes a program focused on preventing and treating sickle cell disease and its complications. It aims to expand research efforts into the causes and potential cures for heritable blood disorders, including sickle cell disease. The bill increases funding for the demonstration program to support these initiatives. Congress expresses a desire for continued research into these conditions.
Key provisions
- Reauthorizes a demonstration program for sickle cell disease prevention and treatment.
- Expands the program's focus to include the prevention and treatment of complications of sickle cell disease.
- Modifies grant-making language to require making grants rather than entering into contracts.
- Increases funding for the program from $4,455,000 per year to $8,205,000 per year, starting in 2025.
Who is affected
- Individuals with sickle cell disease
- Families affected by sickle cell disease
- Researchers studying blood disorders
- Public health agencies
Notable changes
- Increases funding for the sickle cell disease program.
- Broadens the program’s scope to include treatment of complications.
- Changes the language regarding grant agreements.
Fiscal impact
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
7 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours